Lyell Immunopharma reports 93% ORR in 3L+ LBCL for ronde-cel at ASH

Lyell Immunopharma, Inc.

In 3L+ setting (n=29 evaluable): 93% ORR, 76% CR; median PFS 18 months at 12-month median follow-up.
In 2L setting (n=18 evaluable, 94% primary refractory): 83% ORR, 61% CR; median duration of CR not reached.
Safety (n=69): no Grade ≥3 CRS; one Grade ≥3 ICANS case (4% with dex prophylaxis); no treatment-related deaths.
Ronde-cel showed up to 3-fold higher expansion vs approved CD19 CAR-T products and higher memory-cell phenotype.
Data cutoff Sep 5, 2025; ronde-cel is dual-targeting CD19/CD20 CAR-T with CD62L enrichment manufacturing.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.